Neurokinin-1 receptor expression in inflammatory bowel disease: Molecular quantitation and localization

Gut

Volumn 47, Issue 3, 2000, Pages 387-396

  Goode, T ^a   O'Connell, J ^a   Anton, P ^b   Wong, H ^b   Reeve, J ^b   O'Sullivan, G C ^a   Collins, J K ^a   Shanahan, F ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Inflammatory bowel disease; Neurokinin 1 receptor; Substance P

Indexed keywords

NEUROKININ 1 RECEPTOR; SUBSTANCE P;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE HISTOCHEMISTRY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS;

ADULT; AGED; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; FEMALE; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; RECEPTORS, NEUROKININ-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION;

EID: 0033855333     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.3.387     Document Type: Article

References (59)

1. 1 Payan DG. Neuropeptides and inflammation: the role of substance P. Ann Rev Med 1989;40:341-52.
2. 2 McGillis JP, Mitsuhashi M, Payan DG. Immunologie properties of substance P. In: Ader R, ed. Psychoneuroimmmiology, 2nd edn. London: Academic Press, 1991:209-23.
3. 3 Moore TC, Lami JL, Spruck CH. Substance P increases lymphocyte traffic and lymph flow through peripheral lymph nodes of sheep. Immunology 1989;67:109-14.
4. 4 Stanisz AM, Befus D, Bienenstock J. Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferation by lymphocytes from Peyer's patches, mesenteric lymph nodes, and spleen. J Immunol 1986;136:152-6.
5. 5 Payan DG, Brewster DR, Goetzl EJ. Specific stimulation of human T lymphocytes by substance P. J Immunol 1983;131:1613-15.
6. 6 Bost KL, Pascual DW. Substance P: a late acting B lymphocyte differentiation cofactor. Am J Physiol 1992; 262:C537-45.
7. 7 Haines KA, Kolasinski SL, Cronstein BN, et al. Chemoattraction of neutrophils by substance P and transforming growth factor-β1 is inadequately explained by current models of lipid remodelling. J Immunol 1993;151:1491-9.
8. 8 Bar-Shavit Z, Goldman R, Stabinsky Y, et al. Enhancement of phagocytosis - a newly found activity of substance P residing in it's N-terminal tetrapeptide sequence. Biochem Biophys Res Commun 1980;94:1445-51.
9. 9 Shanahan F, Denburg JA, Fox J, et al. Mast cell heterogeneity: effects of neuroenteric peptides on histamine release. J Immunol 1985;135:1331-7.
10. 10 Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 1988;241:1218-21.
11. 11 Ho W-Z, Kaufman D, Uvaydova M, et al. Substance P augments interleukin-10 and tumour necrosis factor-alpha release by human cord monocytes and macrophages. J Neuroimmunol 1996;71:73-80.
12. 12 Pernow B, Substance P. Pharmacol Rev 1983;53:85-141.
13. 13 Maggi CA. Capsaicin-sensitive nerves in the gastrointestinal tract. Arch Int Pharmacol 1990;303:157-66.
14. 14 Sundler F, Hakanson R, Larsson L-I, et al. Substance P in the gut: immunohistochemical and immunocytochemical study of distribution and development. In: von Euler US, Pernow B, eds. Substance P. New York: Raven Press, 1977: 59-65.
15. 15 Shanahan F, Anton PA. Role of peptides in the regulation of the mucosal immune and inflammatory response. In: Walsh JH, Dockray GJ, eds. Gut peptides: biochemistry and physiology. New York: Raven Press, 1994:851-67.
16. 16 Reinshagen M, Egger B, Procaccino F, et al. Neuropeptides in inflammatory bowel disease: an update. Inflamm Bowel Dis 1997;3:303-13.
17. 17 Swain MG, Agro A, Blennerhasset P, et al. Increased levels of substance P in the myenteric plexus of Trichinella-infected rats. Gastroenterology 1992;102:1913-19.
18. 18 Agro A, Stanisz AM. Inhibition of murine intestinal inflammation by anti-substance P antibody. Reg Immunol 1993;5: 120-6.
19. 19 Kataeva G, Agro A, Stanisz AM. Substance P-mediated intestinal inflammation: inhibitory effects of CP 96,345 and SMS 201-995. Neuroimmunomodulation 1994;1:350-6.
20. 20 Pothoulakis C, Castagliuolo I, LaMont TJ, et al. CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc Natl Acad Sci USA 1994;91:947-51.
21. 21 Mantyh CR, Pappas TN, Lapp JA, et al. Substance P activation of enteric neurones in response to intraluminal Clostridium difficile toxin A in the rat ileum. Gastroenterology 1996;111:1272-80.
22. 22 Castagliuolo I, LaMont JT, Letourneau R, et al. Neuronal involvement in the intestinal effects of Clostridium difficile toxin A and Vibrio cholerae enterotoxin in rat ileum. Gastroenterology 1994;107:657-65.
23. 23 Castagiuolo I, Riegler M, Pasha A, et al. Neurokinin-1(NK-1) receptor is required in Clostridium difficile-induced enteritis. J Clin Invest 1998;101:1547-50.
24. 24 Wood JD, Peck OC, Sharma HS, et al. A non-peptide neurokinin-1 (NK-1) receptor antagonist suppresses initiation of acute inflammation in the colon of the cotton-top tamarin model for spontaneous colitis and colon cancer. Gastroenterology 1996;110:A1047.
25. 25 Bernstein CN, Robert ME, Eysselein VE. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. Am J Gastroenterol 1993;88:908-13.
26. 26 Yamamoto H, Morise K, Kusugami K, et al. Abnormal neuropeptide concentration in rectal mucosa of patients with inflammatory bowel disease. J Gastroenterol 1996;31:525-32.
27. 27 Koch TR, Carney A, Go VLW. Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases. Dig Dis Sci 1987;32:369-76.
28. 28 Goldin E, Karmeli F, Sclinger Z, et al. Colonic substance P levels are increased in ulcerative colitis and decreased in chronic severe constipation. Dig Dis Sci 1989;34:754-7.
29. 29 Mazumdar S, Moy Das K. Immunocytochemical localisation of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am J Gastroenterol 1992;87:176-81.
30. 30 Keranen U, Kiviluoto T, Jarvinen H, et al. Changes in substance P-immunoreactive innervation of human colon associated with ulcerative colitis. Dig Dis Sci 1995;40: 2250-8.
31. 31 Watanabe T, Kubota Y, Muto T. Substance P containing nerve fibres in rectal mucosa of ulcerative colitis. Dis Colon Rectum 1997;40:718-25.
32. 32 Kimura M, Masuda T, Hiwatashi N, et al. Changes in neuropeptide-containing nerves in human colonic mucosa with inflammatory bowel disease. Pathol Int 1994;44:624-34.
33. 33 Mantyh CR, Gates TS, Zimmermann RP, et al. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn's disease. Proc Natl Acad Sci USA 1988,85:3235-9.
34. 34 Mantyh CR, Vigna SR, Bollinger RR, et al. Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. Gastroenterology 1995;109:850-60.
35. 35 Mantyh PW, Allen CJ, Ghilardi JR, et al. Rapid endocytosis of a G protein-coupled receptor: Substance P-evoked internalisation of it's receptor in the rat stratum in vivo. Proc Natl Acad Sci USA 1995;92:2622-6.
36. 1) receptor expressed in epithelial cells. Biochem J 1994;303:177-86.
37. 37 Joslin G, Krause JE, Hershey AD, et al. Amyloid β-protein, substance P and bombesin bind to the serpin-enzyme complex receptor. J Biol Chem 1991; 266:21897-902.
38. 38 Marasco WA, Showell HJ, Becker EL. Substance P binds to the formylpeptide chemotaxis receptor on the rabbit neutrophil. Biochem Biophys Res Commun 1981;99:1065-72.
39. 39 Jensen RT, Coy DH. Progress in the development of potent bombesin receptor antagonists. Trends Pharmacol Sci 1991; 12:13-19.
40. 40 Targan S, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside. Baltimore: Williams and Wilkins, 1994.
41. 41 Chomczynski P, Saachi N. Single-step method of RNA isolation by guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
42. 42 O'Connell J, Goode T, Shanahan F. Quantitative measurement of mRNA expression by competitive RT-PCR. Methods Mol Biol 1998;92:183-93.
43. 43 Goode T, O'Connell J, Sternini C, et al. Substance P (neurokinin-1) receptor is a marker of human mucosal but not peripheral mononuclear cells: molecular quantitation and localisation. J Immunol 1998;161:2232-40.
44. 44 Davis DR, Dockerty MB, Mayo CW. The myenteric plexus in regional enteritis: a study of the number of ganglion cells in the ileum in 24 cases. Surg Gynecol Obstet 1955;101:208-16.
45. 45 Dockray GJ. Substance P and other tachykinins. In: Walsh JH, Dockray GJ, eds. Gut peptides: biochemistry and physiology. New York: Raven Press, 1994:401-22.
46. 46 Piatak M, Luk K, Williams B, et al. Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. Biotechniques 1993;14:70-81.
47. 47 Smith VC, Sagot MA, Couraud J-Y, et al. Localisation of the neurokinin 1 (NK-1) receptor in the human antrum and duodenum. Neurosci Lett 1998;253:49-52.
48. 48 Greeno EW, Mantyh P, Vercellotti GM, et al. Functional neurokinin 1 receptors for substance P are expressed by human vascular endothelium. J Exp Med 1993;177:1269-76.
49. 49 Bost KL, Breeding SAL, Pascual DW. Modulation of the mRNAs encoding substance P and it's receptor in rat macrophage by LPS. Reg Immunol 1992;4:105-12.
50. 50 Goode C, O'Connell J, O'Sullivan GC, et al. Cellular localisation and quantitation of substance P (NK-1) receptor mRNA in normal and inflamed human colonie mucosa. Gastroenterology 1997;112:A982.
51. 51 Pothoulakis C, Castagliuolo I, Leeman SE, et al. Substance P receptor expression in intestinal epithelium in Clostridium difficile toxin A enteritis in rats. Am J Physiol 1998;275: G68-75.
52. 52 Castagliuolo I, Keates AC, Wang CC, et al. Clostridrium difficile toxin A stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells. J Immunol 1998; 160:6039-45.
53. 53 Desreumaux P, Brandt E, Gambiez L, et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 1997;113:118-26.
54. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Immunol 1996;157:1261-70.
55. 55 Neissner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 1995;101:428-35.
56. 56 Shanahan F. Enteric neuropathophysiology and inflammatory bowel disease. Neurogastroenterology 1998;10:185-7.
57. 57 Dvorak AM, Connell AB, Dickersin GR. Crohn's disease: a scanning electron microscopic study. Hum Pathol 1979;10: 165-77.
58. 58 Krause JE, DiMaggio DA, McCarson KE. Alterations in neurokinin-1 receptor gene expression in models of pain and inflammation. Can J Physiol Pharmacol 1995;73:854-9.
59. 59 Schafer MK-H, Nohr D, Krause JE, et al. Inflammation-induced upregulation of NK1 receptor mRNA in dorsal horn neurones. Neuroreport 1993;4:1007-10.